[go: up one dir, main page]

WO2012048013A3 - Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections - Google Patents

Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections Download PDF

Info

Publication number
WO2012048013A3
WO2012048013A3 PCT/US2011/054945 US2011054945W WO2012048013A3 WO 2012048013 A3 WO2012048013 A3 WO 2012048013A3 US 2011054945 W US2011054945 W US 2011054945W WO 2012048013 A3 WO2012048013 A3 WO 2012048013A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
nucleoside compounds
guanosine nucleoside
viral injections
phosphorodiamidate derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/054945
Other languages
French (fr)
Other versions
WO2012048013A2 (en
Inventor
Christopher Mcguigan
Mohamed ALJARAH
Karolina MADELA
Claire Bourdin
Sarah Jones
Stanley Chamberlain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Inhibitex Inc
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University, Inhibitex Inc filed Critical University College Cardiff Consultants Ltd
Publication of WO2012048013A2 publication Critical patent/WO2012048013A2/en
Publication of WO2012048013A3 publication Critical patent/WO2012048013A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention is directed to novel compounds of formula (I) having the structure that are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses. Methods of treating viral infections via administration of these compounds are also disclosed.
PCT/US2011/054945 2010-10-06 2011-10-05 Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections Ceased WO2012048013A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39035710P 2010-10-06 2010-10-06
US61/390,357 2010-10-06

Publications (2)

Publication Number Publication Date
WO2012048013A2 WO2012048013A2 (en) 2012-04-12
WO2012048013A3 true WO2012048013A3 (en) 2012-06-14

Family

ID=45928409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054945 Ceased WO2012048013A2 (en) 2010-10-06 2011-10-05 Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections

Country Status (1)

Country Link
WO (1) WO2012048013A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
PT3447061T (en) 2011-03-01 2021-12-23 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
WO2012154321A1 (en) * 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
TW201331221A (en) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
SG11201407674TA (en) * 2012-05-22 2014-12-30 Idenix Pharmaceuticals Inc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
PL2861611T3 (en) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
KR20150027155A (en) 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
CN104936970A (en) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 2'-chloronucleoside analogues for HCV infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP2996696A4 (en) 2013-05-16 2016-12-21 Riboscience Llc NUCLEOSIDE DERIVATIVES SUBSTITUTED 4'-AZIDO, 3'-DEOXY-3'-FLUORO
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
HRP20250266T1 (en) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS
JP2021521118A (en) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド Treatment of HCV-infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138797A1 (en) * 2001-06-29 2003-07-24 Micrologix Biotech Inc. Nucleic acid-based compounds
US20080009461A1 (en) * 2006-06-27 2008-01-10 Biovitrum Ab Therapeutic compounds
US20080286230A1 (en) * 2006-12-28 2008-11-20 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
WO2010081082A2 (en) * 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
US20100233120A1 (en) * 2006-08-11 2010-09-16 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100249056A1 (en) * 2006-05-03 2010-09-30 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138797A1 (en) * 2001-06-29 2003-07-24 Micrologix Biotech Inc. Nucleic acid-based compounds
US20100249056A1 (en) * 2006-05-03 2010-09-30 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
US20080009461A1 (en) * 2006-06-27 2008-01-10 Biovitrum Ab Therapeutic compounds
US20100233120A1 (en) * 2006-08-11 2010-09-16 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20080286230A1 (en) * 2006-12-28 2008-11-20 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
WO2010081082A2 (en) * 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates

Also Published As

Publication number Publication date
WO2012048013A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2012048013A3 (en) Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
WO2012092484A3 (en) Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2010081082A3 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
EA201290053A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
MD20140135A2 (en) Macrocyclic inhibitors of Flaviviridae viruses
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
WO2013040492A3 (en) Methods for treating hcv
NZ748966A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
NZ603310A (en) Heterocyclic flaviviridae virus inhibitors
UA116083C2 (en) PURINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS
UA111841C2 (en) BENZOTHIAZOL COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATION
MX2012008221A (en) Inhibitors of flaviviridae viruses.
NZ600817A (en) Inhibitors of flaviviridae viruses
EA201390538A1 (en) ANTI-VIRUS COMPOUNDS
PL2888241T3 (en) 2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus (HBV) polymerase inhibitors for the treatment of e.g. chronic hepatitis
EA201490015A1 (en) YEAST-BASED COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF INFECTION CAUSED BY THE HEPATITIS DELTA VIRUS
IN2012DN01855A (en)
WO2011041713A3 (en) Piperazinyl antiviral agents
IN2014MN01548A (en)
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EA201000051A1 (en) ANTI-VIRUS COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831528

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11831528

Country of ref document: EP

Kind code of ref document: A2